Darbepoetin Alfa

CHEMBL1201566 Phase 4 Aprobado Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A hyperglycosylated engineered form of erythropoietin with a longer half-life than epoetin alfa, used to stimulate red blood cell production in patients with anemia from chronic kidney disease or chemotherapy. Its modified carbohydrate structure allows less frequent dosing.

Áreas terapéuticas

Enfermedad renal crónica Hematología Nefrología Oncología

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A hyperglycosylated engineered form of erythropoietin with a longer half-life than epoetin alfa, used to stimulate red blood cell production in patients with anemia from chronic kidney disease or chemotherapy. Its modified carbohydrate structure allows less frequent dosing.

Yes, Darbepoetin Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201566. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

¿Busca información accesible para el paciente?

Darbepoetin Alfa en PillFYI

Datos Rápidos

Sinónimos: 1

Enlaces externos

ChEMBL CHEMBL1201566

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.